Korean J Anesthesiol.  2022 Aug;75(4):307-315. 10.4097/kja.22297.

Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent

• Kim SH
• Fechner J

• KMID: 2532109
• DOI: http://doi.org/10.4097/kja.22297

Abstract

Intravenous anesthetic agents such as midazolam, propofol, and ketamine are routinely used to provide anesthesia and sedation. They have been shown to effectively induce and maintain amnesia, sedation, and hypnosis in various patient groups and clinical settings. However, all anesthetic agents have the potential to cause unwanted side effects such as hemodynamic instability, respiratory depression, or slow recovery due to prolonged post-procedural sedation. Remimazolam, a recently approved benzodiazepine for general anesthesia and procedural sedation in Korea, has been successfully used for these purposes. To date, inconclusive knowledge has been obtained regarding the use of remimazolam in different patient populations and under various surgical conditions. With respect to the specific pharmacokinetic and pharmacodynamic characteristics of remimazolam, the use of remimazolam is expected to increase providing safe general anesthesia and sedation. This review aims to provide an overview of the basic and clinical pharmacology of remimazolam and to compare it with midazolam and propofol.

Keyword

Amnesia; Anesthesia; Benzodiazepine; Hypnosis; Remimazolam; Sedation